PRAECIS PHARMACEUTICALS INCORPORATED To Announce Third Quarter Financial Results on Thursday, November 9, 2006

  
    
  
  
    
      PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced 
      that it will report Third Quarter 2006 financial results on Thursday, 
      November 9, 2006, before the financial markets open. Company management 
      will host a conference call beginning at 9:00 a.m., EST, with members of 
      the investment community.
    
    
      The Company’s conference call may be accessed 
      live by visiting PRAECIS’ website at http://www.praecis.com 
      under “Investors” 
      and “Webcast Live.” 
      Interested parties also may listen to a replay of the call beginning 
      Thursday, November 9, at 12:00 Noon, EST, until midnight Friday, 
      November 17, by calling 888-203-1112 or 719-457-0820, and entering the 
      passcode 6471068.
    
    
      PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company 
      focused on the discovery and development of novel compounds that have 
      the potential to address unmet medical needs or improve existing 
      therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical 
      development for cancer indications, including non-Hodgkin’s 
      lymphoma and solid tumors, as well as an innovative drug discovery 
      technology, DirectSelect™, 
      which enables the generation and practical use of ultra large libraries 
      for the discovery of orally active compounds for drug development.
    
  
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today
announced that it will report Third Quarter 2006 financial results on
Thursday, November 9, 2006, before the financial markets open. Company
management will host a conference call beginning at 9:00 a.m., EST,
with members of the investment community.

   The Company's conference call may be accessed live by visiting
PRAECIS' website at http://www.praecis.com under "Investors" and
"Webcast Live." Interested parties also may listen to a replay of the
call beginning Thursday, November 9, at 12:00 Noon, EST, until
midnight Friday, November 17, by calling 888-203-1112 or 719-457-0820,
and entering the passcode 6471068.

   PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical
company focused on the discovery and development of novel compounds
that have the potential to address unmet medical needs or improve
existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458,
in clinical development for cancer indications, including
non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug
discovery technology, DirectSelect(TM), which enables the generation
and practical use of ultra large libraries for the discovery of orally
active compounds for drug development.